The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ifinatamab deruxtecan for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) ...

Findings showed inclacumab did not statistically significantly reduce the rate of VOCs compared with placebo after 48 weeks. Topline data were announced from a phase 3 study evaluating inclacumab, an ...

The approval was supported by data from 3 double-blind, placebo-controlled trials that included a total of 1474 patients who met the 2016 ACR criteria for diagnosis of fibromyalgia.

The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.

The Food and Drug Administration (FDA) has granted Orphan Drug designation to dusquetide (SGX945) for the treatment of Behçet disease, a type of vasculitis characterized by mucocutaneous symptoms (eg, ...

Imagined speech signals were weaker than attempted speech but still accurate enough to reach up to 74% recognition in real time.

HealthDay News — An analysis of more than 13 million electronic health record (EHR) notes shows potential racial bias in how doctors document patient trustworthiness, according to a study published ...

Zopapogene imadenovec is a non-replicating adenoviral vector-based immunotherapy designed to induce an immune response against HPV 6 and HPV 11 proteins.

FluMist is delivered in a temperature-controlled package with at-home specific instructions on the proper handling, administration, and disposal of the vaccine.

Nerve stimulation device cleared for sleep apnea; Skysona safety update; new non-cystic fibrosis bronchiectasis treatment; FDA cracks down on animal-derived thyroid meds; RSV therapy to be ...

The updated recommendations also address the link between high blood pressure and cognitive decline and dementia.

Treatment linked to reduced rates of first occurrence of suicidal behaviors, substance misuse, transport accidents, criminality.